552 related articles for article (PubMed ID: 6597341)
1. Lysis of fresh leukemic blasts by interferon-activated human natural killer cells.
Pattengale PK; Sundstrom C; Yu AL; Levine A
Nat Immun Cell Growth Regul; 1983-1984; 3(4):165-80. PubMed ID: 6597341
[TBL] [Abstract][Full Text] [Related]
2. Antileukemia activity of a natural killer cell line against human leukemias.
Yan Y; Steinherz P; Klingemann HG; Dennig D; Childs BH; McGuirk J; O'Reilly RJ
Clin Cancer Res; 1998 Nov; 4(11):2859-68. PubMed ID: 9829753
[TBL] [Abstract][Full Text] [Related]
3. Stimulating capacity of blast cells from patients with chronic myelocytic leukaemia, in blastic crisis in 'one-way' mixed lymphoycte reaction: lack of evidence for T lymphoblastic conversion.
Han T; Gomez GA; Minowada J
Immunology; 1978 Aug; 35(2):299-305. PubMed ID: 155646
[TBL] [Abstract][Full Text] [Related]
4. Decreased natural killer cell activity in children with untreated acute leukemia.
Nasrallah AG; Miale TD
Cancer Res; 1983 Nov; 43(11):5580-5. PubMed ID: 6352019
[TBL] [Abstract][Full Text] [Related]
5. IFN-gamma treatment of K562 cells inhibits natural killer cell triggering and decreases the susceptibility to lysis by cytoplasmic granules from large granular lymphocytes.
Grönberg A; Ferm MT; Ng J; Reynolds CW; Ortaldo JR
J Immunol; 1988 Jun; 140(12):4397-402. PubMed ID: 3131433
[TBL] [Abstract][Full Text] [Related]
6. Natural killer activity of pediatric patients with acute lymphoblastic leukemia in remission.
Inada M; Okawa H; Suzuki M; Yata J
Jpn J Clin Oncol; 1984 Sep; 14(3):335-45. PubMed ID: 6592376
[TBL] [Abstract][Full Text] [Related]
7. A unique antigen expressed on myeloid cells and acute leukemia blast cells defined by a monoclonal antibody.
Ball ED; Graziano RF; Fanger MW
J Immunol; 1983 Jun; 130(6):2937-41. PubMed ID: 6574189
[TBL] [Abstract][Full Text] [Related]
8. Lysis of fresh human B-lymphocyte-derived leukemia cells by interferon-activated natural killer (NK) cells.
Pattengale PK; Gidlund M; Nilsson K; Sundström C; Sällström J; Simonsson B; Wigzell H
Int J Cancer; 1982 Jan; 29(1):1-7. PubMed ID: 6174459
[TBL] [Abstract][Full Text] [Related]
9. Effects of alpha-interferon on MHC unrestricted cytotoxicity in chronic myelogenous leukemia.
Meseri-Delwail A; Delwail V; Brizard A; Goube de Laforest P; Guilhot F; Lecron JC
Biotechnol Ther; 1994; 5(1-2):47-57. PubMed ID: 7703832
[TBL] [Abstract][Full Text] [Related]
10. Specificity of heteroantisera to human acute leukemia-associated antigens.
Baker MA; Ramachandar K; Taub RN
J Clin Invest; 1974 Dec; 54(6):1273-8. PubMed ID: 4140196
[TBL] [Abstract][Full Text] [Related]
11. Studies on the ability of monoclonal antibodies to selectively mediate complement-dependent cytotoxicity of human myelogenous leukemia blast cells.
Ball ED; Kadushin JM; Schacter B; Fanger MW
J Immunol; 1982 Mar; 128(3):1476-81. PubMed ID: 6948897
[TBL] [Abstract][Full Text] [Related]
12. Expansion of natural killer cells with lytic activity against autologous blasts from adult and pediatric acute lymphoid leukemia patients in complete hematologic remission.
Torelli GF; Guarini A; Maggio R; Alfieri C; Vitale A; Foà R
Haematologica; 2005 Jun; 90(6):785-92. PubMed ID: 15951291
[TBL] [Abstract][Full Text] [Related]
13. Activated natural killer cells from patients with acute myeloid leukemia are cytotoxic against autologous leukemic blasts in NOD/SCID mice.
Siegler U; Kalberer CP; Nowbakht P; Sendelov S; Meyer-Monard S; Wodnar-Filipowicz A
Leukemia; 2005 Dec; 19(12):2215-22. PubMed ID: 16224486
[TBL] [Abstract][Full Text] [Related]
14. Matrix metalloproteinase production by bone marrow mononuclear cells from normal individuals and patients with acute and chronic myeloid leukemia or myelodysplastic syndromes.
Ries C; Loher F; Zang C; Ismair MG; Petrides PE
Clin Cancer Res; 1999 May; 5(5):1115-24. PubMed ID: 10353746
[TBL] [Abstract][Full Text] [Related]
15. VLA-6 (CDw49f) is an important adhesion molecule in NK cell-mediated cytotoxicity following autologous or allogeneic bone marrow transplantation.
Lowdell MW; Shamim F; Hamon M; Macdonald ID; Prentice HG
Exp Hematol; 1995 Dec; 23(14):1530-4. PubMed ID: 8542943
[TBL] [Abstract][Full Text] [Related]
16. Hydroxyurea upregulates NKG2D ligand expression in myeloid leukemia cells synergistically with valproic acid and potentially enhances susceptibility of leukemic cells to natural killer cell-mediated cytolysis.
Lu X; Ohata K; Kondo Y; Espinoza JL; Qi Z; Nakao S
Cancer Sci; 2010 Mar; 101(3):609-15. PubMed ID: 20028385
[TBL] [Abstract][Full Text] [Related]
17. Cell-mediated destruction of human leukemic cells by MHC identical lymphocytes: requirement for a proliferative trigger in vitro.
Sondel PM; O'Brien C; Porter L; Schlossman SF; Chess L
J Immunol; 1976 Dec; 117(6):2197-203. PubMed ID: 1069027
[TBL] [Abstract][Full Text] [Related]
18. The use of VEP13 monoclonal antibody for definition of natural killer cells: spontaneous killer cells directed against fresh human leukaemia cells carry the VEP13 antigen.
Ziegler-Heitbrock HW; Fütterer A; Rumpold H; Kraft D; Munker R; Riethmüller G
Clin Exp Immunol; 1984 Nov; 58(2):470-7. PubMed ID: 6333947
[TBL] [Abstract][Full Text] [Related]
19. Immune escape from a graft-versus-leukemia effect may play a role in the relapse of myeloid leukemias following allogeneic bone marrow transplantation.
Dermime S; Mavroudis D; Jiang YZ; Hensel N; Molldrem J; Barrett AJ
Bone Marrow Transplant; 1997 May; 19(10):989-99. PubMed ID: 9169643
[TBL] [Abstract][Full Text] [Related]
20. Cyclosporine-induced autologous graft-versus-host disease in patients with acute myeloid leukemia undergoing non-myeloablative chemotherapy without progenitor cell reinfusion.
Stein M; Feldman E; Seiter K; Chiao JW; Goff H; Baskind P; Beer M; Ahmed T
Bone Marrow Transplant; 1999 Nov; 24(10):1073-7. PubMed ID: 10578157
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
